Best ectd publishing software

Overview

If you run a regulatory affairs team that compiles, validates, and publishes eCTD sequences in-house, the eCTD publishing software market is narrower than most software categories. This guide covers the five options that came out of our vendor research for this keyword, plus a featured option, and it is worth being direct about what that set contains: two are licensable publishing platforms (DnXT Solutions and Ennov), two are services firms that do the publishing for you rather than selling you software (AXSource and JJCC Group), and one is an enterprise RIM suite (Veeva Vault Submissions) for which limited structured evidence was retained in this comparison. That mix reflects a real feature of this market. Many "eCTD publishing" search results lead to outsourcing partners and consulting firms, not tools your team operates.

This guide is written for a specific buyer: a mid-size pharma or biotech company with roughly a 10-person regulatory affairs and operations team, around 40 eCTD sequences per year across a handful of active FDA and EMA applications, moving publishing in-house after outgrowing outsourced providers. For that buyer, the decision comes down to validation accuracy and rule-set currency, sequence lifecycle management, health authority coverage, document management integration, 21 CFR Part 11 alignment, and pricing transparency.

For that scenario, Assyro is the strongest fit on this list. Its platform pages describe validation that runs upstream during drafting rather than after assembly, pre-configured sequence templates for IND, NDA, BLA, ANDA, and supplement types, and native document sync with SharePoint, Box, and Google Drive, which matches how a 10-person team that authors in existing cloud storage actually works.

Featured Option

Assyro

Best for: Pharma, biotech, and medical device teams preparing FDA regulatory submissions who want validation to happen during drafting, not after publishing.

Assyro is AI regulatory submission software built around a shared submission workspace for drafting, validation, routing, readiness checks, and document and version coordination. Its distinguishing design choice, documented on its document management and submission management pages, is that validation moves upstream: lifecycle conflicts, metadata mismatches, and hyperlink breaks get closed during drafting and review, before publishing, instead of surfacing as a validator report the night before gateway dispatch.

Feature specifics from Assyro's platform documentation:

• In-place CTD authoring. Documents are drafted in their final CTD location (for example, 2.5 or 3.2.P.8.3) from draft one, which removes the reorganize-and-relink step that generates late hyperlink and bookmark fixes.
• Pre-configured eCTD sequence templates for IND, NDA, BLA, ANDA, and supplement types, including module structure, backbone XML, and lifecycle defaults.
• Standardized publishing workflows that encode acceptance criteria once, so every submission runs the same checks, approval steps, and handoff gates without a manually maintained checklist.
• Automatic source-to-submission linkage. For every leaf, the origin document, author, approval timestamp, and change history are retrievable, which is the traceability an auditor asks for.
• Shared content library for reusable sections such as the Module 1.12.1 cover letter and Module 2.2 introduction, with approval tracking preserved on reuse.
• Cross-module review coordination with role-based section ownership, review routing, and approval gates, scoped for 15+ writers across all five modules.
• Publishing-ready output with no Word-to-PDF conversion, bookmark rebuilding, or cross-reference repair at the end of the cycle.

Admin controls include role-based access, audit trails with traceable decisions linked to submission evidence, and workflows aligned to ICH eCTD v4.0.0, 21 CFR Part 11, and GxP documentation expectations. Integrations cover SharePoint, Box, and Google Drive, so a team already authoring in those systems keeps its document home and syncs versions into the submission workspace. Assyro also publishes a free eCTD validator and FDA Orange Book reference tools you can use before any purchase conversation.

Pricing: Custom quote, scoped as an annual contract by team size, workflow mix, and rollout scope, per Assyro's pricing page. A 10-person team falls into the 6-15 person qualification band; pilots are scoped smaller than full deployments. The pricing page cites a "6+ weeks" timeline-saved-per-submission metric and routes buyers through a roughly 2-minute qualification flow before a call. Contact Assyro for a quote tailored to your sequence volume.

Next step: Book a regulatory submission workflow demo to walk through your NDA, ANDA, or IND publishing cycle against Assyro's readiness checks.

Shortlist of the Best ectd publishing software

• Assyro (Featured) — Upstream validation during drafting, eCTD sequence templates for IND/NDA/BLA/ANDA, SharePoint, Box, and Google Drive sync.
• Axsource — Fully outsourced eCTD and NeeS publishing, validation, and gateway filing delivered by regulatory experts, plus SPL labeling and registration services.
• Dnxtsolutions — Cloud-native platform (Publisher, Reviewer, Planner, EDMS) with eCTD 3.x and 4.0 support, coverage of 60+ authorities, and Veeva Vault bidirectional sync.
• Ennov Regulatory Solutions — Ennov Dossier and InSight Publishing with CTD, eCTD, NeeS, VNeeS, and eCopy support, an integrated validator, and eCTD 4.0 pilot experience.
• Jjccgroup — FDA regulatory compliance consulting firm offering outsourced dossier preparation and 510(k) support; not a software product.
• Veeva Vault Submissions — Enterprise submissions module within Veeva Vault RIM; limited structured evidence was available for this comparison.

How We Chose

This shortlist is the full set of options our research resolved for this keyword, not a curation cut from a longer bench. The broader regulatory software market includes other names (LORENZ, EXTEDO, Certara GlobalSubmit, MasterControl, and others appear in the adjacent section below), but those were not researched to the same evidence depth here, so we do not rank them. Do not read this article as complete market coverage; read it as a deep comparison of the options where we could gather comparable evidence.

Our inclusion and evaluation logic was qualitative and auditable:

• Market fit. Does the offering actually address eCTD compilation, validation, and publishing, or does it share the keyword while solving a different problem? We kept services firms in the ranked list because buyers searching this term frequently face the build-vs-outsource decision, but we label them clearly.
• Workflow coverage. Sequence assembly, validation against current FDA and EMA rule sets, lifecycle management, hyperlinking and bookmarking, and gateway-ready output.
• Admin control. 21 CFR Part 11 alignment, audit trails, role-based access, and approval workflows.
• Rollout. What implementation looks like, where documented.
• Integrations. Named connections to document sources such as SharePoint, Box, Google Drive, or Veeva Vault.
• Pricing clarity. Whether a 10-seat team publishing ~40 sequences a year can budget from public information. Notably, no vendor on this list publishes prices, so we compare pricing models instead.

Evidence came from official product and pricing pages, competitor editorial pages used for recall, and public review-site checks. Where review data or feature documentation was thin for a competitor, we say so rather than filling the gap.

Comparison Table

Detailed Reviews

1. Axsource

Fit. AXSource is a regulatory consulting firm, not a licensable software product. Its eCTD publishing and submission services page describes regulatory experts who prepare, compile, publish, validate, and review submissions in eCTD and NeeS formats for the US FDA and Health Canada. If your 10-person team wants hands-on control of ~40 sequences a year, this is not that; if you want to hand the whole publishing function to a partner, it is squarely that.

Standout traits. The service catalog is broad. Beyond Direct, Online & Publishing Services (eCTD, NeeS, format conversions, and paper), AXSource offers Structured Product Labeling (SPL) professional services for both Health Canada and the US FDA, establishment registrations, licenses and listing, annual product and facility renewal services, and application fee management. That means post-approval maintenance work can stay with one vendor, and SPL is a capability most pure publishing tools do not bundle.

Feature specifics. Delivery runs on AXSource Secure Architecture (ASA), the firm's proprietary infrastructure, with validated eCTD software, regular audits, a quality management system, and metadata management covering document content, version, and submission history for retrieval and tracking. Its implementation framework names a clear project timeline, defined roles and responsibilities, staff training, and a quality assurance process. Note that AXSource's named integrations (Salesforce, SAP, Workday, ServiceNow, Dynamics 365 via Azure Integration Services) are separate cloud consulting engagements, not native publishing connectors; document sync with SharePoint, Box, or a regulatory DMS is not described.

Pricing. Quote-based with no public pricing anywhere on axsource.com: no dollar figures, tiers, per-sequence fees, minimum spend, or trial. The only call to action is "Contact Us Today!". For a ~40-sequence year, cost would likely be scoped per sequence or as a retainer, but no rates are published to benchmark against.

Review signals. No G2, Capterra, Software Advice, RAPS, or Reddit user reviews were found; searches on G2 and Capterra returned only similarly named but unrelated products (Axxess, Axure, AssurX). That is consistent with a services firm rather than a reviewed software product, but it means independent user evaluation is not available.

Tradeoffs. You cannot buy seats or run the tooling yourself, budgeting requires a sales conversation with no public benchmark, and there is no product-style integrations directory for document sync.

Bottom line. A legitimate full-outsource option for small-to-mid teams without publishing headcount, and a mismatch for a team deliberately bringing publishing in-house.

2. Dnxtsolutions

Fit. DnXT Solutions is a cloud-native regulatory platform with four connected products: DnXT Publisher (eCTD compilation, validation, and publishing), DnXT Reviewer (Part 11-compliant collaborative review), DnXT Planner (Gantt-based submission planning), and DnXT EDMS (AI-classified document management). It targets mid-size pharma, biotech, and CROs, which puts it directly in range for a 10-seat team, and it pairs the software with regulatory consulting and publishing services, per dnxtsolutions.com.

Standout traits. DnXT Publisher supports eCTD 3.x and 4.0 (HL7 RPS) with coverage for FDA, EMA, Health Canada, PMDA, TGA, SAHPRA, and 60+ authorities in total. Validation is part of the core subscription rather than a separate paid module: preflight checks run during assembly, final validation runs before publishing, and current FDA and EMA rule sets are maintained as part of the subscription. "Spec Intelligence" validates against the latest agency specifications before submission, and AI cross-reference linking automatically creates hyperlinks across modules to reduce manual hyperlink errors.

Feature specifics. A three-layer hybrid AI classification engine identifies document types, suggests eCTD placement, and flags anomalies before validation. Named integrations include Veeva Vault (bidirectional sync, so documents flow without manual export/import), Veeva PromoMats (with automatic Form 2253 generation for AdPromo), Box, Egnyte, SharePoint, and SSO via Azure AD and Okta. Compliance certifications listed on the site include SOC 2 Type II, 21 CFR Part 11, HIPAA, GDPR, and GxP validation (IQ/OQ/PQ). Real-time dashboards show submission status, document readiness, and milestones.

Pricing. Quote-based, per-tenant pricing scoped to submission volume and portfolio complexity rather than headcount, per DnXT's comparison page. All 10 seats would be included without per-seat fees, and users can be added without renegotiating the contract. A 12-week implementation (configuration, validation protocol execution, training, parallel publishing) is part of onboarding. No dollar figures are published anywhere on dnxtsolutions.com.

Review signals. No public review-site data was retained for this vendor, so independent user sentiment cannot be cited.

Tradeoffs. The vendor footprint is small: the homepage cites 20+ customers and 340+ submissions published, and third-party estimates put the team at roughly 11-20 employees founded in 2024, a scale risk versus decades-old incumbents. It is also cloud-only with no on-premise option described, which will not fit organizations with validated on-prem infrastructure requirements.

Bottom line. The strongest choice on this list for multi-region filings or a Veeva Vault-anchored document stack, if you can accept a young vendor.

3. Ennov Regulatory Solutions

Fit. Ennov offers regulatory publishing software, Ennov Dossier and Ennov InSight Publishing, that lets teams build, manage, publish, validate, and archive eCTD and other submission dossiers on its 21 CFR Part 11-compliant platform, per en.ennov.com. Following its acquisition of Calyx's Enterprise Technology division (the Liquent InSight suite), it is an established option for teams that want publishing and document management from a single vendor.

Standout traits. Format and region coverage is the widest on this list: CTD, eCTD, NeeS, VNeeS, and eCopy, with built-in submission assembly templates for the US, EU, GCC, Canada, Swissmedic, and TGA, and regular template updates as regulatory guidance changes. An integrated eCTD validator produces interactive reports for corrective action, so sequences can be checked against required specifications before gateway dispatch without a separate validation tool. Ennov's eCTD Content Hub cites 11 successful eCTD 4.0 pilot submissions across the EMA, FDA, and PMDA.

Feature specifics. Publishing automatically generates required ICH and regional XML files, correctly named leaf files, and folder structures. Navigation aids include hyperlinking, bookmarking, and table of contents creation. InSight Publishing supports drag-and-drop document linking into assemblies, content linking from multiple document locations, and electronic (eCTD/NeeS) and paper submissions from a common interface, with multiple regional submissions from the same assembly. Publishing is intrinsically connected to Ennov Doc, its EDMS, giving automated dossier lifecycles, workflows, notifications, and metadata-based navigation. The platform carries ISO/IEC 27001 and ISO 9001:2015 certifications.

Pricing. Quote-based with no pricing published anywhere on en.ennov.com for Dossier, InSight Publishing, or the platform. A 10-seat team publishing ~40 sequences a year must request a custom quote. Ennov's platform page states that platform-wide updates are included for customers at no additional cost.

Review signals. No public review-site data was retained for this vendor, so independent user sentiment cannot be cited.

Tradeoffs. The deepest value assumes adopting the broader Ennov stack: full dossier management is described as available "when combined with Ennov Regulatory Documents," a heavier footprint than a standalone publishing tool. No named third-party SaaS integrations or SSO/SAML/SCIM details are published; teams needing SharePoint, Box, or Google Drive sync would rely on custom REST API work (only an Office 365 collaborative authoring integration for Ennov Doc is named).

Bottom line. The best fit for multi-region, multi-format publishing standardized on one vendor's EDMS-plus-publishing stack, and a heavier lift for a team that wants to keep documents where they already live.

4. Jjccgroup

Fit. JJCC Group is an FDA regulatory compliance consulting firm with 30+ years of experience across medical devices, pharmaceuticals, dietary supplements, food, and tobacco/nicotine products. It sells no eCTD publishing software. Its eCTD pages, including its eCTD publishing software guide, are editorial buyer's guides comparing third-party tools such as EXTEDOpulse and Certara GlobalSubmit. Its own engagements are quote-based consulting: FDA submissions, QMS buildout, ISO 13485, 510(k) preparation, audits, and dossier preparation done on the client's behalf.

Standout traits. The team includes scientists, toxicologists, regulatory specialists, quality professionals, and medical and technical writers. Hands-on submission support spans first-time 510(k) preparation (including product classification analysis and predicate device identification), gap analyses, mock audits, warning-letter remediation, CAPA management, and post-market surveillance. Quality-system coverage runs across ISO 13485, FDA 21 CFR Part 820, EU MDR, MDSAP, 21 CFR Part 111, and 21 CFR Part 117, with SOP development, supplier qualification, and mock FDA inspections.

Feature specifics. As a service, deliverables include outsourced CTD/eCTD dossier preparation, toxicology study guidance under FDA GLP requirements, customized staff compliance training, and direct support during official FDA inspections. Its published software guide covers advanced validation with automated fixes, smart updates and content inheritance, multi-format output (eCTD, NeeS, PDF) from a single source, and dashboards tracking IND/NDA/MAA status, useful orientation for early vendor discovery. No integrations apply, since there is no software product to integrate.

Pricing. Quote-based consulting with no rate card. JJCC's own regulatory approval consulting page cites industry-average specialist consultant costs of "$5,000 to $18,000" for an initial retainer and hourly rates between "$125 and $400" as market context, not a JJCC price list. Its own guide's cost logic cuts against outsourcing at volume: consulting cost structure scales with usage rather than flattening, so 40 sequences a year of outsourced publishing could exceed the cost of an owned platform.

Review signals. No G2, Capterra, Software Advice, TrustRadius, RAPS, or Reddit listings were found; the only feedback located was unverified client testimonials on jjccgroup.org, which we exclude. The absence of software review-site listings is consistent with a consulting firm.

Tradeoffs. A 10-seat team wanting to compile, validate, and publish in-house cannot license anything from JJCC, and budget comparison against per-seat software vendors is impossible at shortlisting stage.

Bottom line. A credible partner when the gap is regulatory strategy, audit readiness, or a first 510(k), not a publishing software answer.

5. Veeva Vault Submissions

Fit. Veeva Vault Submissions is the submissions module within Veeva's Vault RIM suite, per veeva.com. Veeva is a widely recognized name in life sciences software, but limited public documentation was retained in this research for independent evaluation: the evidence set for this vendor contains no feature list, no named integrations, no compliance detail, and no pricing signal beyond "pricing not obvious."

Standout traits. Based on its positioning within Vault RIM, the product addresses regulatory submissions as part of a broader regulatory information management suite. We cannot responsibly enumerate specific capabilities, health authority coverage, or validation behavior from the evidence available here.

Feature specifics. Not retained in this comparison. Buyers should request Veeva's product documentation directly, including its eCTD publishing and validation capabilities, health authority coverage, and Part 11 controls, and hold it to the same checkpoints listed in the Key Features section below.

Pricing. Not obvious from public sources reviewed here. No pricing model, tier structure, or per-seat information was retained, so a 10-seat / ~40-sequence budget estimate is not possible.

Review signals. No review-site data was retained for this vendor in this research, so ratings and user sentiment cannot be cited.

Tradeoffs. The practical tradeoff for a shortlisting buyer is diligence effort: unlike DnXT and Ennov, whose sites document formats, validators, and integrations in detail, this comparison cannot verify Veeva Vault Submissions' publishing specifics without direct vendor engagement. Enterprise RIM suites also typically imply a larger platform commitment than a standalone publishing tool, which a 10-person team should scope carefully.

Bottom line. Worth a direct evaluation if you are already in or moving toward the Veeva ecosystem; this guide cannot rank its publishing capabilities on evidence.

How to Choose the Right ectd publishing software

Work through these filters in order.

1. In-house software or outsourced service? This is the fork that splits this market. If you are moving publishing in-house, as the 10-seat / ~40-sequence buyer profile here is, your real candidates are Assyro, Dnxtsolutions, Ennov, and (pending direct diligence) Veeva Vault Submissions. If you lack publishing headcount and want to hand off the function, Axsource does the work for you, and Jjccgroup fits when the need is regulatory strategy or a first 510(k) rather than publishing at all.

2. Where do you want validation to happen? If your recurring pain is late-cycle validator reports, broken hyperlinks, and sequence rebuilds before dispatch, Assyro is the recommended default: its documented approach closes lifecycle conflicts, metadata mismatches, and hyperlink breaks during drafting and review, with documents authored in their final CTD location from draft one. If you prefer validation integrated at assembly and publish time, DnXT runs preflight checks during assembly with rule sets maintained in the subscription, and Ennov ships an integrated validator with interactive corrective-action reports.

3. Which health authorities and formats do you file to? For FDA-centric IND, NDA, BLA, ANDA, and supplement work, Assyro's pre-configured sequence templates and ICH eCTD v4.0.0-aligned workflows cover the need. For filings across many regions, Dnxtsolutions (60+ authorities, eCTD 3.x and 4.0) and Ennov (US, EU, GCC, Canada, Swissmedic, TGA templates plus NeeS, VNeeS, and eCopy) go wider.

4. Where do your documents live? If your team authors in SharePoint, Box, or Google Drive, Assyro connects to all three natively. If your documents live in Veeva Vault, DnXT's bidirectional Vault sync is the documented answer. If you want the publishing tool and the EDMS from one vendor, Ennov's native Ennov Doc connection is the fit, at the cost of a heavier stack.

5. How will you budget? Every option here is quote-based, so compare models instead of prices. DnXT's per-tenant model scoped to submission volume avoids per-seat math. Assyro scopes annual contracts by team size, workflow mix, and rollout, with pilots priced smaller than full deployments; for the 10-seat scenario, contact Assyro for a quote in the 6-15 person band.

Key Features to Look For in ectd publishing software

• Validation accuracy and rule-set currency. Ask each vendor how FDA and EMA technical rule sets are updated and whether validation is included or an add-on. DnXT maintains rule sets within the subscription; Ennov's validator is integrated with interactive reports. Assyro goes a step further on timing by running readiness checks during drafting, and its free public eCTD validator lets you test the approach before buying.
• Sequence lifecycle management. Confirm support for the submission types you file. Assyro ships templates for IND, NDA, BLA, ANDA, and supplements with lifecycle defaults; Ennov manages eCTD sequences and metadata with dossier lifecycle management.
• Health authority format coverage. Match coverage to your actual filing map: Ennov for CTD/eCTD/NeeS/VNeeS/eCopy across six template regions, DnXT for 60+ authorities and eCTD 4.0 (HL7 RPS), Assyro for FDA-focused work aligned to ICH eCTD v4.0.0.
• Document management integration. The best publishing tool is the one that connects to where your documents already are. Assyro names SharePoint, Box, and Google Drive; DnXT names Veeva Vault, Box, Egnyte, and SharePoint; Ennov assumes its own Ennov Doc EDMS.
• Part 11 compliance and audit trail depth. Look for per-leaf traceability, not just an audit log. Assyro's source-to-submission linkage retrieves origin document, author, approval timestamp, and change history per leaf; DnXT documents Part 11 e-signatures with full audit history; Ennov's platform is Part 11-compliant with ISO 27001 certification.
• Hyperlink and bookmark handling. Late hyperlink fixes are a leading cause of sequence rebuilds. DnXT automates cross-reference linking with AI; Ennov automates hyperlinking, bookmarking, and TOC creation; Assyro's in-place authoring prevents the reorganize-and-relink problem from occurring.
• Pricing model fit. With no public prices in this market, the model matters: per-tenant (DnXT), scoped annual contract (Assyro), or custom quote (Ennov, Axsource, Jjccgroup).

Pricing and Cost Considerations

None of the six options in this guide publishes list prices, so the honest comparison for a 10-seat team publishing ~40 eCTD sequences per year across 6 active applications is a comparison of pricing models and quote inputs.

Three cost dynamics to watch. First, seat-based versus volume-based scoping: DnXT prices per tenant on submission volume, so adding reviewers costs nothing, while Assyro scopes by team size band and workflow mix, so contact Assyro to understand how sequence volume affects your quote. Second, validation as an add-on: DnXT explicitly includes validation in the core subscription, and you should ask every other vendor whether validation is bundled or a separate module. Third, services cost scaling: per JJCC's own guide, consulting costs scale with usage rather than flattening, so at ~40 sequences per year, outsourced publishing can exceed the cost of an owned platform, which is the financial case for bringing publishing in-house in the first place.

Adjacent Options in the ectd publishing software Landscape

These tools and resources overlap with the keyword but were not researched to ranked-list depth here, or solve a different workflow:

• LORENZ docuBridge — a long-established submission management product; not evaluated to evidence depth in this comparison.
• EXTEDO eCTDmanager — a submission management product from EXTEDO; not evaluated to evidence depth here.
• Certara GlobalSubmit — Certara's eCTD publishing, validation, and review line; not evaluated to evidence depth here.
• MasterControl — quality management software with eCTD-related pages; its core workflow is QMS rather than eCTD publishing.
• Masuu NextGen eCTD — an eCTD offering from Masuu Global; limited evidence retained.
• eCTD Tool (ectdtool.com) — an eCTD-focused site; limited evidence retained.
• FDA eCTD resources (fda.gov) — the agency's official eCTD specifications and guidance, essential reading but not software.
• Global Regulatory Writing & Consulting (globalrwc.com) — publishes eCTD submission guidance content; a services and content resource, not a publishing tool.

Assyro vs Other Options

Assyro vs Axsource. Assyro is licensable software with in-place CTD authoring, pre-configured IND/NDA/BLA/ANDA sequence templates, and native SharePoint, Box, and Google Drive sync; Axsource is an outsourced services firm whose experts compile, publish, and validate eCTD/NeeS sequences on your behalf. Both are quote-based. Assyro wins for a dedicated regulatory team taking publishing in-house; Axsource wins for a small team without publishing headcount that also wants SPL labeling and establishment registrations handled.

Assyro vs Dnxtsolutions. Dnxtsolutions differentiates on global reach and Veeva depth: eCTD 3.x and 4.0 (HL7 RPS) across FDA, EMA, Health Canada, and 60+ authorities, Veeva Vault bidirectional sync, and per-tenant pricing scoped to submission volume. Assyro is FDA-focused with ICH eCTD v4.0.0-aligned workflows, upstream validation during drafting, a shared content library, and SharePoint, Box, and Google Drive sync. Assyro wins for US-centric teams prioritizing authoring-stage validation; Dnxtsolutions wins for multi-region filings or Vault-anchored stacks, accepting a small vendor footprint (20+ customers, founded 2024).

Assyro vs Ennov Regulatory Solutions. Ennov wins on format and region breadth (CTD, eCTD, NeeS, VNeeS, eCopy across US, EU, GCC, Canada, Swissmedic, and TGA, plus 11 eCTD 4.0 pilots across EMA, FDA, and PMDA), but publishes no SharePoint, Box, or Google Drive connectors and assumes its Ennov Doc EDMS for full value. Assyro connects natively to those cloud stores and pushes validation upstream into drafting. Assyro wins for FDA-focused teams keeping documents in existing cloud storage; Ennov wins for multi-region publishing standardized on one vendor's EDMS-plus-publishing stack.

Assyro vs Jjccgroup. Jjccgroup sells no eCTD publishing software; it is a 30+ year FDA consulting firm handling 510(k) preparation, QMS buildout (ISO 13485, 21 CFR Part 820), and dossier preparation on the client's behalf, with its own guide citing industry-typical retainers of "$5,000 to $18,000" and hourly rates of "$125 and $400". Assyro is the actual tooling a team runs itself. Assyro wins for compiling and validating ~40 sequences a year in-house; Jjccgroup wins when the gap is regulatory strategy, audit readiness, or a first 510(k).

Assyro vs Veeva Vault Submissions. The evidence available for Veeva Vault Submissions contains no feature list, integrations, or pricing detail, so a grounded head-to-head is not possible from this data. Assyro documents concrete capabilities: in-place CTD authoring, IND/NDA/BLA/ANDA sequence templates, and SharePoint, Box, and Google Drive sync. Assyro wins on documented, verifiable publishing capability today; buyers already committed to Vault RIM should request Veeva's feature and pricing documentation directly before deciding.

FAQ

Do any of these vendors publish prices?

No. All six options are quote-based with no public dollar figures for licenses, seats, or sequences. The nearest public anchors are JJCC's cited industry-average consulting retainers of "$5,000 to $18,000" with hourly rates of "$125 and $400", which describe the consulting market generally, not any vendor's rate card. Budget by comparing pricing models: per-tenant on submission volume (DnXT), annual contract scoped by team size and workflows (Assyro), or fully custom quotes (the rest).

Should a team at ~40 sequences per year own software or keep outsourcing?

The volume math favors owning. Per JJCC's own guide, consulting costs scale with usage rather than flattening, so recurring sequence volume across multiple active applications tends to make an owned platform cheaper over time, along with faster turnaround and internal lifecycle knowledge. Outsourcing (Axsource) still makes sense at low volume or with no publishing headcount.

How do I verify a vendor's validation rule sets are current?

Ask directly how FDA and EMA technical rule-set updates are delivered and whether they cost extra. DnXT states rule sets are maintained within the subscription; Ennov provides regular template updates as guidance changes. You can also cross-check any vendor's output with an independent check; Assyro publishes a free eCTD validator at assyro.com/tools/ectd-validator you can run against a sequence before dispatch.

What about eCTD 4.0 readiness?

Three vendors document it: Assyro describes ICH eCTD v4.0.0-aligned workflows, DnXT Publisher supports eCTD 4.0 (HL7 RPS), and Ennov cites 11 eCTD 4.0 pilot submissions across the EMA, FDA, and PMDA. Ask any vendor you shortlist for their v3-to-v4 transition plan for your existing application lifecycles.

Is 21 CFR Part 11 compliance consistent across these options?

The software vendors all document Part 11 alignment: Assyro (Part 11-aligned workflows with per-leaf audit trails), DnXT (Part 11 e-signatures with full audit history, plus SOC 2 Type II and GxP validation), and Ennov (platform-wide Part 11 compliance with ISO 27001). For services firms, ask how their internal systems and your records handoff maintain Part 11 traceability on your side.

Conclusion

For a 10-person regulatory team bringing ~40 eCTD sequences a year in-house across FDA and EMA filings, Assyro is the default recommendation in this guide. Its documented approach, validation and readiness checks that run during drafting, in-place CTD authoring, sequence templates for IND, NDA, BLA, ANDA, and supplements, and native SharePoint, Box, and Google Drive sync, targets the specific failure modes (late hyperlink fixes, metadata mismatches, sequence rebuilds) that make publishing cycles slip. Book a regulatory submission workflow demo at assyro.com to test it against your next sequence.

Route to a competitor when your constraints genuinely differ. Choose Dnxtsolutions for multi-region filings across 60+ authorities or a Veeva Vault document stack, accepting a young vendor. Choose Ennov Regulatory Solutions for the broadest format coverage (eCTD, NeeS, VNeeS, eCopy) on a single EDMS-plus-publishing stack. Choose Axsource to outsource publishing entirely rather than license software. Choose Jjccgroup for regulatory strategy, audit remediation, or a first 510(k), not publishing tooling. And evaluate Veeva Vault Submissions directly if you are committed to the Vault RIM ecosystem, since its publishing specifics could not be verified from the evidence here. Whichever direction you take, run a dummy sequence through each finalist's validator before you sign.